KOAGULOPATIJA I KOVID 19
Sažetak
Interesovanje za kovid 19 u svetu nauke ne prestaje. Patogeneza kovida 19 i dalje je predmet velikog broja studija, a koagulopatija zauzima važno mesto u istraživanjima. Glavni cilj ovog rada bilo je ispitivanje karakteristika koagulopatije izazvane kovidom 19. Za potrebe ove studije prikupljeni su uzorci krvi 131 bolesnika koji se zbog infekcije SARS-CoV-2 prvi put bolnički lečio u Univerzitetskom kliničkom centru u Kragujevcu. Uzorak krvi uzet je na dan prijema, a potom je praćen tok bolesti. Došlo se do zaključka da ovi ispitanici ne ispunjavaju kriterijume za diseminovanu intravaskularnu koagulaciju (DIK). Polazeći od forme i ishoda bolesti, predstavili smo statistički značaj broja trombocita, vrednosti protrombinskog vremena i DIK skora. Pacijenti sa kritičnom formom bolesti, kao i oni kod kojih je ova bolest dovela do smrtnog ishoda, imali su značajno niže vrednosti broja trombocita, a značajno veće vrednosti DIK skora.
Reference
A practical guide to haemostasis. ISTH DIC Scoring Algorithm. Available at: https://practical-haemostasis.com/. Accessed on December 1,2022.
Ackermann M, Verleden SE, Kuehnel M, Haverich A, Welte T, Laenger F, et al. Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19. N Engl J Med 2020;383(2):120-8. [CrossRef] [PubMed]
Al-Saadi EAKD, Abdulnabi MA. Hematological changes associated with COVID-19 infection. J Clin Lab Anal 2022;36(1):e24064. [CrossRef] [PubMed]
Anwar N, Tashfeen S, Akhtar F, Noor A, Khan SA, Omair A. Can disseminated intravascular coagulation scores predict mortality in COVID-19 patients? J Taibah Univ Med Sci 2021;16(4):596-604. [CrossRef] [PubMed]
Asakura H, Ogawa H. COVID-19-associated coagulopathy and disseminated intravascular coagulation. Int J Hematol 2021;113(1):45-57. [CrossRef] [PubMed]
Barale C, Melchionda E, Morotti A, Russo I. Prothrombotic Phenotype in COVID-19: Focus on Platelets. Int J Mol Sci 2021;22(24):13638. [CrossRef] [PubMed]
Carsana L, Sonzogni A, Nasr A, Rossi RS, Pellegrinelli A, Zerbi P, et al. Pulmonary post-mortem findings in a series of COVID-19 cases from northern Italy: a two-centre descriptive study. Lancet Infect Dis 2020;20(10):1135-40. [CrossRef] [PubMed]
Comer SP, Cullivan S, Szklanna PB, Weiss L, Cullen S, Kelliher S, et al. COVID-19 induces a hyperactive phenotype in circulating platelets. PLoS Biol 2021;19(2):e3001109. [CrossRef] [PubMed]
Flaumenhaft R, Enjyoji K, Schmaier AA. Vasculopathy in COVID-19. Blood 2022;140(3):222-35. [CrossRef] [PubMed]
Fox SE, Akmatbekov A, Harbert JL, Li G, Quincy Brown J, Vander Heide RS. Pulmonary and cardiac pathology in African American patients with COVID-19: an autopsy series from New Orleans. Lancet Respir Med 2020;8(7):681-6. [CrossRef] [PubMed]
Gerber GF, Chaturvedi S. How to recognize and manage COVID-19-associated coagulopathy. Hematology Am Soc Hematol Educ Program 2021;2021(1):614-20. [CrossRef] [PubMed]
Hadid T, Kafri Z, Al-Katib A. Coagulation and anticoagulation in COVID-19. Blood Rev 2021;47:100761. [CrossRef] [PubMed]
Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395(10223):497-506. [CrossRef] [PubMed]
Jose RJ, Manuel A. COVID-19 cytokine storm: the interplay between inflammation and coagulation. Lancet Respir Med 2020;8(6):e46-e47. [CrossRef] [PubMed]
Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ; HLH Across Speciality Collaboration, UK. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet 2020;395(10229):1033-4. [CrossRef] [PubMed]
Nasif WA, El-Moursy Ali AS, Hasan Mukhtar M, Alhuzali AMH, Yahya Alnashri YA, Ahmed Gadah ZI, et al. Elucidating the Correlation of D-Dimer Levels with COVID-19 Severity: A Scoping Review. Anemia 2022;2022:9104209. [CrossRef] [PubMed]
Portier I, Campbell RA, Denorme F. Mechanisms of immunothrombosis in COVID-19. Curr Opin Hematol 2021;28(6):445-53. [CrossRef] [PubMed]
Qu R, Ling Y, Zhang YH, Wei LY, Chen X, Li XM, et al. Platelet-to-lymphocyte ratio is associated with prognosis in patients with coronavirus disease-19. J Med Virol 2020;92(9):1533-41. [CrossRef] [PubMed]
Teimury A, Khameneh MT, Khaledi EM. Major coagulation disorders and parameters in COVID-19 patients. Eur J Med Res 2022;27(1):25. [CrossRef] [PubMed]
Thilagar B, Beidoun M, Rhoades R, Kaatz S. COVID-19 and thrombosis: searching for evidence. Hematology Am Soc Hematol Educ Program 2021;2021(1):621-7. [CrossRef] [PubMed]
Wang J, Jiang M, Chen X, Montaner LJ. Cytokine storm and leukocyte changes in mild versus severe SARS-CoV-2 infection: Review of 3939 COVID-19 patients in China and emerging pathogenesis and therapy concepts. J Leukoc Biol 2020;108(1):17-41. [CrossRef] [PubMed]
Weiss SL, Peters MJ, Alhazzani W, Agus MSD, Flori HR, Inwald DP, et al. Surviving sepsis campaign international guidelines for the management of septic shock and sepsis-associated organ dysfunction in children. Intensive Care Med 2020;46(Suppl 1):10-67. [CrossRef] [PubMed]
Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review. JAMA 2020;324(8):782-93. [CrossRef] [PubMed]
World Health Organization. Therapeutics and COVID-19: living guideline. 2022 September. Available at: https://www.who.int/publications/i/item/WHO-2019-nCoV therapeutics-2022.5, Accessed December 1,2022
